NASDAQ$SCPX
Scorpius Holdings Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Provided strategic, financial, and operational updates for the year ended December 31, 2021.
Heat Biologics, Inc. provided strategic, financial, and operational updates for the year ended December 31, 2021. The company highlighted the progress of its clinical programs, including HS-110 for non-small cell lung cancer and PTX-35 for solid tumors, as well as its biomanufacturing capabilities and biodefense initiatives.
- Presented favorable survival data of HS-110 in combination with checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC).
- Announced additional dose levels for Phase 1 clinical trial evaluating the safety of PTX-35 monotherapy in patients with solid tumors.
- Broke ground on a new biomanufacturing facility in San Antonio, Texas, through Scorpion Biological Services.
- Announced a definitive merger agreement to acquire Elusys Therapeutics, a commercial-stage biodefense company.
Headline financials
Revenue & EPS history
Scorpius Holdings · Revenue · Quarterly
$613K
Revenue by segment
Scorpius Holdings · $459K total across 1 segment · Q2 2021
- Grant and Contract Revenue$459K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-0.3%
Avg return
Earnings day
+100.8%
Avg return
5 days after
+129.2%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+5.2%
Q1 2021
Best reaction
-9.6%
Q3 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | +0.0% | +1350.0% | +3100.0% | |
| Q2 2025 | +0.0% | +900.0% | -60.0% | |
| Q1 2025 | -1.4% | +0.7% | +4.1% | |
| Q4 2024 | +0.0% | -1.5% | -2.9% | |
| Q1 2026 | +2.8% | -41.4% | -41.1% | |
| Q1 2024 | +2.8% | -41.4% | -41.1% | |
| Q3 2024 | +3.5% | +12.6% | -35.6% | |
| Q4 2023 | +0.0% | +2.1% | -19.1% | |
| Q3 2023 | -0.8% | -13.7% | -34.5% | |
| Q2 2023 | -1.6% | -12.9% | -2.9% | |
| Q1 2023 | -0.0% | -4.0% | -24.6% | |
| Q4 2022 | -0.0% | -4.0% | -24.6% | |
| Q3 2022 | +2.3% | -4.4% | -33.6% | |
| Q2 2022 | +0.4% | -11.5% | -22.2% | |
| Q1 2022 | -1.0% | -5.8% | -23.3% | |
| Q4 2021 | -9.4% | +12.4% | +17.9% | |
| Q3 2021 | -2.5% | -7.2% | -21.6% | |
| Q2 2021 | +1.2% | -4.3% | -4.1% | |
| Q1 2021 | +5.2% | +6.2% | -0.7% | |
| Q4 2020 | +1.8% | -8.9% | -10.3% | |
| Q3 2020 | -9.6% | -7.0% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro